Courting controversy

Suzanne J Farley

doi:10.1038/ncpneph0194 | Full Text | PDF (68K)

Can glomerulosclerosis be reversed?

Agnes B Fogo

Even advanced sclerotic glomeruli show ongoing cell turnover, indicating that there is potential for modulation of the progressive renal scarring seen in chronic kidney disease. Agnes Fogo examines the mechanisms of glomerulosclerosis, with a particular focus on the pivotal role of angiotensin, and considers the potential reversibility of the processes involved.

doi:10.1038/ncpneph0200 | Full Text | PDF (93K)

Further insights into the renal effects of drugs that disrupt the renin–angiotensin system

Rachael Williams

doi:10.1038/ncpneph0162 | Full Text | PDF (94K)

Pediatric patients on hemodialysis experience increased arterial stiffness

Pippa Murdie

doi:10.1038/ncpneph0163 | Full Text | PDF (81K)

Determining the cause of fast transport status in peritoneal dialysis patients

Rebecca Ireland

doi:10.1038/ncpneph0185 | Full Text | PDF (95K)

Novel treatment improves intradialytic hypotension

Rebecca Ireland

doi:10.1038/ncpneph0165 | Full Text | PDF (98K)

A noninvasive proteomic method for early detection of renal allograft rejection

Rachael Williams

doi:10.1038/ncpneph0171 | Full Text | PDF (95K)

Reversal of kidney damage in pancreas transplant recipients

Jim Casey

doi:10.1038/ncpneph0164 | Full Text | PDF (82K)

The antiviral properties of leflunomide in renal allograft recipients

Rachael Williams

doi:10.1038/ncpneph0170 | Full Text | PDF (81K)

Genetic characterization of autosomal recessive polycystic kidney disease

Jim Casey

doi:10.1038/ncpneph0173 | Full Text | PDF (84K)

Standard assays underestimate the prevalence of albuminuria

Jim Casey

doi:10.1038/ncpneph0174 | Full Text | PDF (93K)

Reversing the progression of polycystic kidney disease with an mTOR inhibitor

Rachael Williams

doi:10.1038/ncpneph0186 | Full Text | PDF (83K)

Sevelamer for treating hyperphosphatemia in pediatric CKD patients

Rachael Williams

doi:10.1038/ncpneph0175 | Full Text | PDF (97K)

Modified buttonhole cannulation technique for fistulae with aneurysmal dilatation

Rebecca Ireland

doi:10.1038/ncpneph0187 | Full Text | PDF (91K)

Downloadable models for predicting solute clearance

Pippa Murdie

doi:10.1038/ncpneph0172 | Full Text | PDF (84K)

Is Thymoglobulin^® a safe treatment for renal graft rejection in patients with HIV?

Jim Casey

doi:10.1038/ncpneph0176 | Full Text | PDF (83K)

Doses of histamine-2-receptor antagonists should be reduced in patients with low glomerular filtration rate

Gary R Matzke

doi:10.1038/ncpneph0182 | Full Text | PDF (96K)

Equations used to predict glomerular filtration rate perform poorly in kidney transplant recipients

Paul E de Jong

doi:10.1038/ncpneph0153 | Full Text | PDF (93K)

Kidney paired donation: a single-center study of feasibility and outcomes

Douglas J Norman

doi:10.1038/ncpneph0188 | Full Text | PDF (91K)

Home fingerprick sampling for immunosuppressant drug monitoring in pediatric renal transplant patients

Philip D Acott

doi:10.1038/ncpneph0181 | Full Text | PDF (91K)

Does pravastatin safely and effectively improve lipid profiles in children who have received a kidney transplant?

Douglas M Silverstein

doi:10.1038/ncpneph0183 | Full Text | PDF (93K)

Hypercalciuria in children with decreased muscle mass—urine calcium : osmolality versus urine calcium : creatinine

William G van't Hoff

doi:10.1038/ncpneph0193 | Full Text | PDF (93K)

Adding spironolactone to conventional antihypertensives reduces albuminuria in patients with diabetic nephropathy

Murray Epstein

doi:10.1038/ncpneph0192 | Full Text | PDF (95K)

Do patients with type 2 diabetes on peritoneal dialysis need less insulin if they are given rosiglitazone?

Werner A Scherbaum

doi:10.1038/ncpneph0199 | Full Text | PDF (95K)

Drug Insight: renal indications of calcimimetics

Irina Shahapuni, Matthieu Monge, Roxana Oprisiu, Hakim Mazouz, Pierre-François Westeel, Philippe Morinière, Ziad Massy, Gabriel Choukroun and Albert Fournier

This Review focuses on the role of drugs such as cinacalcet in the treatment of uremic secondary hyperparathyroidism. The authors present evidence to support their assertion that cinacalcet plus higher doses of calcium-based oral phosphate binders is a safe and efficacious alternative to currently recommended regimens. Other indications for calcimimetic drugs, such as predialysis secondary hyperparathyroidism and hypercalcemic hyperparathyroidism following kidney transplantation, are also discussed.

doi:10.1038/ncpneph0191 | Full Text | PDF (190K)

Reappraisal of 2003 NKF-K/DOQI guidelines for management of hyperparathyroidism in chronic kidney disease patients

Matthieu Monge, Irina Shahapuni, Roxana Oprisiu, Najeh El Esper, Philippe Morinière, Ziad Massy, Gabriel Choukroun and Albert Fournier

Since the latest K/DOQI guidelines were formulated, new data on drugs such as lanthanum carbonate and calcimimetics have become available. In light of this new information, Matthieu Monge and colleagues believe that current practice can be updated. In this Review, the authors outline their recommendations regarding drug selection, dosing regimens, and monitoring of hyperparathyroidism in dialysis patients.

doi:10.1038/ncpneph0189 | Full Text | PDF (274K)

Guidelines for disorders of mineral metabolism and secondary hyperparathyroidism should not yet be modified

Joachim H Ix, L Darryl Quarles and Glenn M Chertow

In the third article of our series on secondary hyperparathyroidism in renal disease, Joachim Ix and colleagues comment on the recommendations put forth by Matthieu Monge et al. on page 326. Ix et al. contend that the changes to current practice proposed by Monge and colleagues are supported by insufficient evidence and should be revisited only when more data from high-quality trials become available.

doi:10.1038/ncpneph0190 | Full Text | PDF (118K)